Regeneron Pharmaceuticals Inc (REGN) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Total Assets Chart for Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc (REGN) total assets for FY2025 were USD 40.6B, a 7.4% change from FY2024. Regeneron Pharmaceuticals Inc's total assets grew from USD 25.4M in 1990 to USD 40.6B in 2025 (159579.9% over 35 years). Total assets compound annual growth rate: 5-year CAGR of 18.8%, 10-year CAGR of 21.9%, 20-year CAGR of 25.6%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$79.49B
Implied Share Price
$785.98
Enterprise Value
$73.03B
Revenue (TTM)
$15.53B
EBITDA
$4.70B
Profit Margin
27.87%
Trailing P/E
19.01
Forward P/E
16.61
Price/Book (MRQ)
2.47
Price/Sales (TTM)
5.12
EV/EBITDA
12.70
EV/Revenue
4.70
Dividend Yield
0.47%
Book Value
$316.11
Free Cash Flow (FY2025)
$4.08B
Free Cash Flow Yield
5.13%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.